Ymmunobio to Present Pre-Clinical Data at Annual Meeting of the Society for Immunotherapy of Cancer

Ymmunobio to Present Pre-Clinical Data on the Anti-Cancer Activity of Lead Asset YB-200 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer.

Read more here: https://www.biopharmadive.com/press-release/20221012-ymmunobio-to-present-pre-clinical-data-on-the-anti-cancer-activity-of-lead/